Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
430.50    -4.50 (-1.03%)
Bid:
429.50
Ask:
431.50
Spread: 2.00 (0.466%)
Market Cap: £211.73m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

10 Jul 2015 07:00

RNS Number : 6817S
Zotefoams PLC
10 July 2015
 



Zotefoams plc

("Zotefoams" or "the Company")

 

Trading Update

 

 

10 July 2015 - Zotefoams, a world leader in cellular material technology, today provides a trading update for the six months ended 30 June 2015.

 

For the first six months of 2015 Zotefoams will deliver sales1 growth of approximately 8%, which is approximately 10% on a constant currency basis. Zotefoams expects revenue from MuCell Extrusion LLC, the Company's technology licensing business, to grow by around 40% and High-Performance Products ("HPP") sales growth to exceed 20%, building on the very strong HPP performance in 2014. The Company's Polyolefin foams sales volumes have increased by 6% and this is expected to deliver an increase in revenue of approximately 5%, equivalent to around 8% in constant currency. All three business units have strong forward order books.

 

The price of LDPE (Low Density Polyethylene), the Company's major raw material, was at a similar average euro price to the first half of 2014, although prices have risen sharply in recent months. The weaker euro has benefitted raw material purchases, which are significantly euro based, and US dollar sales have benefitted from the stronger dollar. However this has been more than offset by the impact of the euro on both Zotefoams' European sales and, in particular, the unhedged translational impact on the Company's balance sheet.

 

In Walton, Kentucky, USA, the major investment to increase global manufacturing capacity in support of future growth is proceeding to schedule.

 

Whilst being mindful of the potential impact of economic conditions the Company continues to expect 2015 to be another year of progress and remains confident about the long-term prospects for the business.

 

Zotefoams expects to announce its interim results for the six months ended 30 June 2015 on Tuesday 4 August 2015.

 

 

Enquiries:

Zotefoams plc

David Stirling, Group CEO

0208-664-1600

Clifford Hurst, Finance Director

FTI Consulting

0203-727-1000

Victoria Foster Mitchell/Simon Conway

 

 

Notes

 

1 Sales consolidates all external sales made by the joint-ventures as well as those made by Zotefoams plc and its subsidiaries.

2 Foreign exchange rates were:

 

H1:2015 average

H1:2014 average

30 Jun 2015

31 Dec 2014

Euro

1.378

1.223

1.412

1.289

USD

1.530

1.673

1.574

1.559

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

ZOTEK® is a registered trademark of Zotefoams plc. MuCell® is a registered trademark of Trexel Inc. T-Tubes® is a registered trademark of UFP Technologies Inc.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFMGGNZLMGKZZ
Date   Source Headline
12th Jul 202212:39 pmRNSDirector/PDMR Shareholding
8th Jul 20227:00 amRNSNotice of Results
30th Jun 20224:52 pmRNSDirector/PDMR Shareholding
8th Jun 20224:40 pmRNSSecond Price Monitoring Extn
8th Jun 20224:35 pmRNSPrice Monitoring Extension
8th Jun 20228:49 amRNSDirector/PDMR Shareholding
26th May 20224:41 pmRNSSecond Price Monitoring Extn
26th May 20224:36 pmRNSPrice Monitoring Extension
25th May 20221:04 pmRNSResult of the 2022 Annual General Meeting
25th May 20227:00 amRNSTrading Update
18th May 20224:41 pmRNSSecond Price Monitoring Extn
18th May 20224:36 pmRNSPrice Monitoring Extension
12th May 20223:58 pmRNSDirector/PDMR Shareholding
11th May 20222:13 pmRNSDirector/PDMR Shareholding
25th Apr 20225:16 pmRNSDirector/PDMR Shareholding
25th Apr 20227:00 amRNS2021 Annual Report and Notice of the 2022 AGM
11th Apr 20223:49 pmRNSDirector/PDMR Shareholding
22nd Mar 20227:00 amRNSPreliminary Results
14th Mar 202212:30 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSNotice of results and investor presentation
15th Feb 20224:26 pmRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSFull Year Trading Update
12th Jan 202211:12 amRNSDirector/PDMR Shareholding
23rd Dec 20211:56 pmRNSDirector/PDMR Shareholding
17th Dec 20217:00 amRNSTrading Update
14th Dec 202111:55 amRNSDirector/PDMR Shareholding
12th Nov 202112:41 pmRNSDirector/PDMR Shareholding
10th Nov 20215:48 pmRNSHolding(s) in Company
4th Nov 20215:59 pmRNSHolding(s) in Company
4th Nov 20213:31 pmRNSDirector/PDMR Shareholding
3rd Nov 20217:00 amRNSQ3 Trading Update
15th Oct 202112:10 pmRNSDirector/PDMR Shareholding
12th Oct 202111:05 amRNSDirector/PDMR Shareholding
1st Oct 20213:31 pmRNSHolding(s) in Company
14th Sep 202110:05 amRNSDirector/PDMR Shareholding
12th Aug 20212:28 pmRNSDirector/PDMR Shareholding
10th Aug 20217:00 amRNSInterim Results
19th Jul 20219:26 amRNSNotice of Results
13th Jul 20211:59 pmRNSDirector/PDMR Shareholding
14th Jun 20213:06 pmRNSDirector/PDMR Shareholding
14th Jun 202111:35 amRNSDirector/PDMR Shareholding
10th Jun 20214:41 pmRNSDirector/PDMR Shareholding
9th Jun 20213:48 pmRNSDirector/PDMR Shareholding
2nd Jun 20213:49 pmRNSHolding(s) in Company
26th May 202112:08 pmRNSResult of AGM
26th May 20217:00 amRNSTrading Update
12th May 20213:44 pmRNSDirector/PDMR Shareholding
28th Apr 20212:05 pmRNSDirector/PDMR Shareholding
26th Apr 20213:16 pmRNS2020 Annual Report, Notice of the 2021 AGM
13th Apr 20212:06 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.